This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Non Hodgkin's lymphoma

Authoring team

Non-Hodgkin's lymphoma (NHL) is a malignant proliferation of lymphocytes

NHL is the sixth most common cancer in the UK.

There are many different subtypes of the disease, with markedly different clinical courses and requirements for therapy. Diagnosing non-Hodgkin's lymphoma and identifying the precise subtype is challenging, and optimising the diagnostic process is central to improved management (1)

  • majority derives from B cells (around 85-90%) and the remainder from T lymphocytes or natural killer (NK) cells (2).

The aetiology of most cases of NHL is unknown. Possible aetiologic factors include:

  • Epstein Barr virus - linked to Burkitt’s lymphoma
  • human herpesvirus 8 – related to diffuse large B cell lymphoma
  • human immunodeficiency virus – in AIDS-associated NHLs
  • helicobacter pylori - gastric MALT NHL
  • hepatitis C virus (3)

It is important to diagnose NHL as some cases are curable and most are treatable

The prognosis depends on the histologic type, stage, and treatment (4).

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.